GAPO syndrome
Rare autosomal recessive disorder causing growth retardation and premature aging.
GAPO syndrome is an uncommon genetic condition passed down in an autosomal recessive pattern. It causes major delays in growth, along with hair loss, teeth that never break through the gums, and, in some people, worsening damage to the optic nerve. The disorder’s name comes from these main features: growth retardation, alopecia, pseudoanodontia, and optic atrophy. Fewer than 30 instances had been recorded by 2011, and the first known case was described in 1947. People with GAPO syndrome often die prematurely, typically between the ages of 30 and 40, because of interstitial fibrosis and atherosclerosis.
The condition is marked by slow bone development, which leads to a shorter-than-average height. Hair is usually thin and brittle, often resulting in baldness later in life. Tooth growth is also stunted, so teeth either don’t emerge from the gums or don’t form properly. About one-third of those affected experience optic nerve atrophy, which reduces peripheral vision and makes it harder to distinguish colors. Although not a core symptom, many individuals have coarse facial features, an unusually large forehead, a flat nasal bridge, protruding ears, and thick lips. The middle part of the face often looks abnormal. There is no clear link between GAPO syndrome and intellectual disability, though some cases have reported both.
Diagnosis is possible very early, often by six months of age, and most symptoms are clear by age two. The disorder is caused by mutations in both copies of the ANTXR1 gene, located on chromosome 2. This gene normally helps build actin, a protein essential for cell structure. When it’s disrupted, the actin network doesn’t work properly, leading to a buildup of extracellular matrix and weakened cell adhesions. The mutations can be nonsense changes or alterations that affect RNA splicing, resulting in a different or modified protein. Because the condition is so rare, most confirmed cases involve a history of inbreeding among ancestors.
There is no cure for GAPO syndrome, but some symptoms can be managed. Nearsightedness, which occurs in some patients, can be corrected with glasses. Optic atrophy, however, cannot be reversed. Corticosteroids have been suggested as a possible treatment for optic nerve damage, but their effectiveness is debated, and no steroid-based therapies are currently available.
Quick Facts
- Frequency
- < 1 per million
Facts from the source article.
Lore & Background
GAPO syndrome is caused by a deletion in both copies of the ANTXR1 gene, which encodes Anthrax Toxin Receptor 1. This gene is critical for the creation of actin; its disruption inhibits proper function of the actin network, leading to a buildup of extracellular matrix and degraded cell adhesions. The alteration can occur as nonsense mutations or splice-site mutations, and the gene is located on chromosome 2 with 22 exons. The disorder is inherited in an autosomal recessive fashion, requiring both parents to pass on the mutant genotype, and most confirmed cases have a history of ancestral inbreeding.
Principal symptoms include growth retardation from slow skeletal formation, alopecia with thinly dispersed and fragile hair often leading to baldness, pseudoanodontia where teeth fail to emerge from the gums, and optic atrophy in about one third of individuals, causing inhibited peripheral vision and difficulty distinguishing colours. Most individuals have coarse facial features, a large forehead, depressed nose bridge, protruding ears, and abnormally thick lips. No direct correlation has been found with intellectual disability, though cases of both have been reported.
Diagnosis can be made very early, with most cases diagnosed by 6 months of age and symptoms apparent by age 2. There is no cure; nearsightedness can be treated with corrective lenses, but optic atrophy cannot be corrected. Corticosteroids have been proposed for optic nerve atrophy but their effectiveness is disputed, and no steroid-based treatments are currently available.
Reader's Guide
GAPO syndrome is significant as an extremely rare genetic disorder that illustrates the critical role of the ANTXR1 gene in actin network function and extracellular matrix regulation. Its acronym encapsulates the core features—growth retardation, alopecia, pseudoanodontia, and optic atrophy—which together produce a distinctive phenotype that can be diagnosed in infancy. The disorder's autosomal recessive inheritance pattern and association with ancestral inbreeding highlight genetic isolation effects. The identification of ANTXR1 mutations as causative provides a molecular basis for understanding the syndrome's pathology, including the buildup of extracellular matrix and degraded cell adhesions. Despite its rarity, GAPO syndrome contributes to broader knowledge of connective tissue disorders and premature aging mechanisms. The lack of effective treatments for optic atrophy and the disputed role of corticosteroids underscore the need for further research. The syndrome's natural history, with premature death typically in the fourth decade from interstitial fibrosis and atherosclerosis, marks it as a severe condition with limited management options.
Did You Know?
- GAPO syndrome was first reported in 1947 by Anderson and Pindborg, with no further case recorded until 1978.
- The ANTXR1 gene, which causes GAPO syndrome when mutated, is located on chromosome 2 and has 22 exons.
- Optic atrophy occurs in approximately one third of individuals with GAPO syndrome, leading to inhibited peripheral vision and difficulty distinguishing colours.
- Most cases of GAPO syndrome can be diagnosed by 6 months of age, with all symptoms apparent by age 2.
More in Genetic disorders with OMIM but no gene 1-24
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced